Biotechnology News
Cutting edge news about companies engaged in the research and development of new drugs, medical devices and procedures as well as research, books and information on FDA approvals, patents and awards. Biotechnology news highlights the use of biological processes, organisms or systems to manufacture products that improve the quality of life.
Augie’s Quest to Cure ALS Completes $5.8 Million Commitment to Fund ALS TDI’s Translational Research Center
The ALS Therapy Development Institute (ALS TDI) is proud to announce that Augie’s Quest to Cure ALS has fulfilled its $5.8 million commitment, pledged in 2021, to advance ALS research. This transformative funding has directly supported the Augie’s Quest Translational Research Center... - December 13, 2024 - ALS Therapy Development Institute
Regenexx Announces Dr. Philippe Hernigou as New Medical Director of Clinical Research
Regenexx®, a leader in regenerative medicine and advanced orthobiologics, is proud to announce that Dr. Philippe Hernigou, a globally recognized expert in autologous cell therapy and musculoskeletal regeneration, has joined the company as its new Medical Director of Clinical Research. Dr. - December 11, 2024 - Regenexx
Let’s Win Pancreatic Cancer Selects TrialX to Launch Its First AI-Powered Global Clinical Trial Finder
Let’s Win Pancreatic Cancer, a go-to resource that guides patients and caregivers with vital information for better outcomes, launches a new global AI-based clinical trial finder - powered by TrialX - that aims to increase accessibility of clinical trial information for patients and families affected by pancreatic cancer. - November 19, 2024 - TrialX
Recode Ventures, in Partnership with Lilly, Launches Recode Edge, a Multi-Million Dollar Program to Enable AI-Powered Healthcare Innovations
Recode Ventures is excited to announce Eli Lilly and Company (Lilly) as the Founding Partner of Recode Edge, a groundbreaking multi-million dollar investment program for early-stage AI-first healthcare startups. Recode Edge is open to innovative founders worldwide who are building AI-driven solutions to tackle some of the most critical challenges in healthcare. The most promising companies will receive equity investment to support their growth and impact. - November 12, 2024 - Recode Ventures
NeuroDex Awarded Target ALS Biomarker Consortia Grant to Drive Advancements in ALS Research
NeuroDex Awarded Target ALS Biomarker Consortia Grant to Drive Advancements in ALS Research - November 09, 2024 - NeuroDex
NanoCellect Biomedical Announces Strategic Partnership with Additional Distributors Across the APAC Region
NanoCellect Biomedical, a leading provider of innovative microfluidic flow cytometry solutions, is excited to announce new strategic partnerships with additional distributors in the Asia-Pacific (APAC) region. These partnerships will further expand NanoCellect’s presence in these key markets,... - November 08, 2024 - NanoCellect Biomedical
Creative Biolabs Shines at the 2024 NIH Research Festival: Showcasing Antibody Solutions
Creative Biolabs made a splash at the 2024 NIH Research Festival, held from Sept. 23–25, as they highlighted their groundbreaking work in antibody discovery and development. - November 08, 2024 - Creative Biolabs
Polar Lab Projects Redefines Laboratory Relocation Standards with Global, Single-Source Logistics Solution
Polar Lab Projects is setting a new standard in laboratory relocations and logistics, offering a single-source, seamless solution tailored to the life sciences industry worldwide. With an extensive network of industry experts, they provide unmatched service excellence, meeting clients' needs wherever they operate. - November 06, 2024 - Polar Lab Projects LLC
Synaps Dx Launches Digital Cognitive Screening and Alzheimer’s Testing with BrainCheck and Clarity Health Clinics
Synaps Dx, BrainCheck, and Clarity Health introduce an innovative online Alzheimer's and cognitive health screening tool, accessible from home. Launching in Texas, with nationwide expansion planned, this telehealth solution provides families with a convenient, reliable path to early detection during National Alzheimer’s Disease Awareness Month, reducing the need for in-office visits and empowering proactive cognitive care. - November 04, 2024 - SynapsDx
GlycoMira Therapeutics Receives Key Patent for First-in-Class Oncology Therapeutic
Key patent covering GlycoMira's lead compound GM-1111 adds to the Company's already strong IP portfolio. - November 04, 2024 - GlycoMira Therapeutics, Inc.
Aptitude Health Acquires Athena Meetings & Events, Organizer of the Annual UK Oncology Forum, to Strengthen Global Reach
Aptitude Health, a global leader in evidence-based oncology and hematology insights, announces the acquisition of Athena Meetings & Events, a global meetings and events company with over 25 years of experience in the pharmaceutical and healthcare sectors. This strategic acquisition will enable... - November 01, 2024 - Aptitude Health
NuvOx Announces Two New Publications
Co-Founders, Dr. Evan Unger and Dr. Jennifer LH Johnson combine efforts to publish 2 journal articles that help explain how the NuvOx drug candidate - NanO2TM works. Artificial Cells, Nanomedicine, and Biotechnology published Dodecafluoropentane emulsion as an oxygen therapeutic, an article that... - October 31, 2024 - NuvOx Therapeutics
RESCUE-II Trial Demonstrates the Feasibility of On-The-Table Pharmacomechanical Lysis
RESCUE-II Trial Demonstrates the Feasibility of On-The-Table Pharmacomechanical Lysis without Post-Procedure Infusion in Treating Acute Pulmonary Embolism - October 28, 2024 - Thrombolex, Inc.
Thrombolex Announces the First Two Patients Enrolled in the RAPID-PE Clinical Study
Thrombolex, Inc. announced the enrollment of the first two patients in the RAPID-PE study using the BASHIR™ Endovascular Catheter for the treatment of acute pulmonary embolism by Dr. Ayman Iskander, interventional cardiologist at St. Joseph’s Health Hospital in Syracuse, NY. The... - October 23, 2024 - Thrombolex, Inc.
Parvus Announces First Human Subject Dosed in a Clinical Trial with PVT201, a First-in-Class Off-the-Shelf Regulatory T-cell (Treg) Inducing pMHC Nanomedicine Therapy
Parvus Therapeutics, a private clinical-stage biopharmaceutical company developing a pipeline of novel treatments for autoimmune disease announced the successful dosing of the first subject in a Phase 1/2, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PVT201 single ascending doses in healthy subjects and primary biliary cholangitis patients. - October 17, 2024 - Parvus Therapeutics U.S., Inc.
Greenberg Regenerative Medicine Celebrates Nearing 2 Years of Success with Pioneering VSEL Therapy
Greenberg Regenerative Medicine is approaching its two-year milestone of offering Very Small Embryonic-Like (VSEL) stem cell therapy at their Bryn Mawr, PA clinic. VSEL therapy has proven highly effective in treating diverse conditions by enhancing the body’s natural healing. Under Dr. Scott Greenberg's leadership, VSEL therapy is now a key component of their advanced regenerative treatment offerings. - September 27, 2024 - Greenberg Regenerative Medicine
BÜHLMANN Laboratories AG Announces Worldwide Collaboration with Beckman Coulter for BUHLMANN fCAL® turbo and fPELA® turbo Assays
BÜHLMANN Laboratories AG, a leading manufacturer of specialty, high-quality in-vitro diagnostic and research assays, is pleased to announce the collaboration with Beckman Coulter for a worldwide distribution of the BÜHLMANN fCAL® turbo assay & BÜHLMANN fPELA® turbo assay... - September 26, 2024 - BUHLMANN Diagnostics Corp
NuvOx Pharma LLC Announces Receipt of Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medical Products
NuvOx Pharma LLC, a wholly owned subsidiary of NuvOx Therapeutics Inc. (together, “NuvOx”) announced that it has received a Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medicinal Products Manufactured outside of EU (in Third Countries) . This... - September 21, 2024 - NuvOx Therapeutics
J3 Bioscience, Inc. Announces Commercial Launch of Groundbreaking LivRing®
J3 Bioscience, Inc., a startup women’s health medical device company, today announced the commercial launch of a first-of-its-kind medical device, LivRing®. This innovative device has the potential to conveniently ease painful sex due to vaginal dryness and improve the lives of countless... - September 18, 2024 - J3 Bioscience, Inc.
US Biologic, Inc. and the Agricultural Research Service Announce Breakthrough Oral Alternative to Antibiotics for Poultry
US Biologic, Inc. and the U.S. Department of Agriculture’s Agricultural Research Service (ARS) announce today findings of a new alternative to antibiotics in the face of coccidiosis and antimicrobial resistance, which cost the poultry industry $3.5B in annual losses worldwide and endanger the... - September 17, 2024 - US Biologic, Inc.
Cromos Pharma Announces the Opening of a New Office in Portugal
Cromos Pharma has opened a new office in Lisbon, Portugal, expanding its presence in Southern Europe. Portugal’s robust healthcare system, EU regulatory alignment, and diverse patient population make it an ideal site for clinical trials. This expansion bolsters Cromos Pharma’s European operations and underscores its commitment to patient-centered research, offering its "No Patients – No Payment" model to minimize sponsor risk. - September 17, 2024 - Cromos Pharma
Valis Corporation Technology Used in Large Brain Model Project
Using Quantum-Entangled Brain Organoids for Artificial Natural and General Intelligence - September 16, 2024 - Valis Corp
Sama Therapeutics and Quine Biologics Announce Collaboration to Develop Breakthrough Antibody Therapeutics for Neurological Disorders
Sama Therapeutics and Quine Biologics have partnered to develop an innovative therapy for neurological disorders, combining AI-driven platforms and advanced antibody engineering. The collaboration focuses on biologics that precisely target the central nervous system, minimizing side effects. By integrating Sama's generative AI with Quine's antibody design expertise, the project addresses unmet medical needs and advances treatments for conditions like Alzheimer’s and multiple sclerosis. - September 13, 2024 - Quine Biologics, Inc.
Microvascular Therapeutics Announce Completion of Phase 2 Study Enrollment for MVT-100
Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the completion of enrollment in MVT’s Phase 2 program using its microbubble product, MVT-100, for endocardial border delineation. This study, An Ascending Dose Comparison of... - September 13, 2024 - Microvascular Therapeutics, Inc.
Huntington Study Group and HD Genetics Collaborate to Better Serve HD Gene Positive Patients
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce a strategic partnership with HD Genetics to assist patients who have tested positive for Huntington’s disease (HD) learn about and enroll in research studies. There remains a... - September 05, 2024 - Huntington Study Group
ICH1132 Shows Promise in Early-Stage Tumor Growth Inhibition Studies
New comparative study of ichorbio's anti-PD-1 antibody clone RMP1-14 highlights potential for optimized cancer research protocols. - August 21, 2024 - ichorbio Ltd
Huntington Study Group Announces New CEO
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce that Daniel Claassen, MD, MS, an internationally recognized Huntington’s Disease neurologist and researcher has accepted the role as the organization’s Chief Executive... - August 20, 2024 - Huntington Study Group
Parvus Therapeutics Announces Leadership Appointments to Support Development from Preclinical Into Clinical
New Positions Enhance Parvus Capability to Execute the Translation of Multiple Drug Candidates into the Clinic. - August 06, 2024 - Parvus Therapeutics U.S., Inc.
Creative Biolabs Spearheads Innovative Live Biotherapeutics Against Gut Diseases
Creative Biolabs introduces innovative solutions for live biotherapeutics to empower scientists and pharmaceutical companies in their quest for groundbreaking therapies against gut diseases. - August 03, 2024 - Creative Biolabs
New Study Explores Potential Benefits of Biophoton Generators in Alzheimer's Care
Study results shared at Alzheimer's Association International Conference in Philadelphia. - July 30, 2024 - Tesla BioHealing, Inc.
Thrombolex and Aidoc Announce Strategic Partnership to Advance Breakthrough Pulmonary Embolism Treatment
Thrombolex, Inc., an innovator in the development of advanced interventional medical devices for the treatment of thromboembolic disease, and Aidoc, a pioneering force in clinical AI, are pleased to announce a strategic partnership aimed at revolutionizing the treatment of acute pulmonary embolism... - July 30, 2024 - Thrombolex, Inc.
Leap Years®: Supports Age-Related Cognitive Decline in Dogs and Quality Time Together with Owners Through NAD+ Enrichment
Animal Biosciences Announces Peer-Reviewed Publication of a Clinical Trial to Evaluate the Slowing of Age-Related Signs in Dogs. After five years of development, clinical results are published regarding senior dog aging in a rigorous, placebo-controlled trial performed at a North Carolina State University College of Veterinary Medicine. - July 23, 2024 - Leap Years
U.S. Precision Medicine, Inc. Signs MOU to Deploy microNeb’s VIGIL Series Inhaler Technology to Enhance Absorption of Its New Drug Candidate in IND Process
U.S. Precision Medicine, Inc. (USPM) has signed a Memorandum of Understanding (MOU) to deploy microNeb's advanced inhaler technology to expedite the uptake of its new cancer drug candidate currently in the Investigational New Drug (IND) process. - July 16, 2024 - microNeb, Inc.
MC4R Agonist Drug Candidates Demonstrate Potential to Transform GLP1 Obesity Therapy
Courage Therapeutics announced new evidence of synergy between MC4R agonists and GLP1RA drugs in a paper published in the Journal of Clinical Investigation led by co-founder Dr. Roger Cone. The company has completed a drug discovery campaign to invent a best in class portfolio of MC4R agonists for obesity in order to leverage the synergy. Potential combinations with drugs such as Ozempic and Mounjaro could improve side effects such as nausea and GI discomfort while driving increased weight loss. - July 16, 2024 - Courage Therapeutics
SYNAPS Dx Welcomes Renowned Alzheimer’s Researcher, Dr. Donna Wilcock, to Its Scientific Advisory Board
SYNAPS Dx welcomes Dr. Donna M. Wilcock, a leading Alzheimer's researcher, to its Scientific Advisory Board. Dr. Wilcock's expertise in neuroinflammation and vascular cognitive impairment will support the advancement of the DISCERN™ diagnostic test for Alzheimer's disease. This addition reinforces SYNAPS Dx’s commitment to pioneering accurate, minimally invasive diagnostics for Alzheimer's. For more info, visit SYNAPS Dx's website. - July 15, 2024 - SynapsDx
Huntington Study Group Announces Launch of LEAD-HD Observational Study
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) today announce the release of their newest Patient Reported Outcomes (PRO) study, LEAD-HD. This observational study was developed collaboratively with the University of Rochester Center for Health +... - July 15, 2024 - Huntington Study Group
NuvOx Pharma LLC Announces Authorization of ARDS Trial from Health Canada
NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II Trials. Evan Unger, MD, CEO of NuvOx, said, “Acute Respiratory Distress... - July 12, 2024 - NuvOx Therapeutics
Morningbird Space Corporation Announces Release of Its Revolutionary 3D Printer Backed by NASA
The Electronic Alchemy eforge series 3.1 is a revolutionary 3D printer capable of creating fully functional electronic devices. The printer was supported by NASA SBIR/STTR and is ready for pre-order. Sensors, circuits, elements, wearable tech, biotechnology, rapid prototyping, and much more is capable with the proprietary filaments from this groundbreaking FDM machine. - July 11, 2024 - Morningbird Space Corporation
SYNAPS Dx Announces Expansion to New, State-of-the-Art Facility
SYNAPS Dx has moved to a new, state-of-the-art facility in Rockville, MD, to meet growing demand and enhance patient care. The larger space and advanced infrastructure will support more diagnostic samples and ensure timely, accurate Alzheimer's and dementia diagnoses. Fully qualified for high-complexity clinical lab testing, the facility boosts diagnostic capabilities. The expansion will also advance the DISCERN™ test, a minimally invasive tool distinguishing Alzheimer's from other dementias. - June 26, 2024 - SynapsDx
Cambridge Polymer Group Unveils Restructure to Accelerate Client Innovation through Material Science
Cambridge Polymer Group (CPG) announced a new leadership structure to better support clients in developing innovative products. CPG is creating a new five-person senior management team with deep materials science expertise, which will allow for closer collaboration with clients on complex projects. Dr. Gavin Braithwaite will be the new CEO and Dr. Stephen Spiegelberg will move to the new role of Chief Scientific Officer (CSO). - June 23, 2024 - Cambridge Polymer Group
M4 Engineering Inc. Acquires Phoenix Technology Works a New Prototyping Powerhouse is Created
M4 Engineering Inc., a leading Engineering, Test, and Prototyping firm in the field of conceptual design, analysis and product development has acquired Phoenix Technology Works (PTW) Maricopa, AZ to increase its footprint in full vehicle prototyping and tooling for composite applications. The... - June 14, 2024 - M4 Engineering
Sosemo LLC Awarded on the Financial Times Americas’ Fastest Growing Companies 2024 List
Sosemo LLC Awarded on the Financial Times Americas’ Fastest Growing Companies 2024 List Sosemo LLC has been awarded on the Financial Times list of The Americas’ Fastest Growing Companies 2024. This prestigious award is presented by the Financial Times and Statista Inc., the... - May 30, 2024 - Sosemo
International Perinatal Stem Cell Society, Inc. and TRI-PAC Health and Wellness Advocacy Have Formed a Strategic Alliance to Advance Stem Cell Legislation
The International Perinatal Stem Cell Society, Inc. and TRI-PAC Health and Wellness Advocacy have formed a strategic alliance to advocate for legal access to safe, effective, and affordable stem cell therapies in the United States. They propose adopting the Japanese model for stem cell therapy regulation, allowing patients to participate in paid clinical trials. The partnership aims to draft and propose a federal bill to improve patient access to stem cell and tissue therapies. - May 24, 2024 - International Perinatal Stem Cell Society, Inc.
RoddyMedical Selected for Mayo Clinic & ASU MedTech Accelerator Program
Company Meets with Top Experts and Brings Home Audience Choice Award - May 23, 2024 - RoddyMedical Inc.
Creative Biolabs Opens Applications for the 2024 Scholarship Program
Creative Biolabs, a leading CRO, is proud to announce the opening of applications for its 2024 scholarship program. This initiative aims to provide financial assistance to students within the biotechnology industry, supporting their academic pursuits and research endeavors. - May 19, 2024 - Creative Biolabs
Revolutionizing Clinical Trials: AnzuBridge Unveils Next-Generation Solutions for Improved Efficacy Evaluations in the Treatment of Rare Disease
AnzuBridge® updates its CDMS to enhance biotech evaluations with advanced video tools, ensuring precise efficacy recording and compliance. It supports scalable trials and features HIPAA-compliant media capture, ePRO for patient engagement, and sophisticated video review capabilities, all integrated with a Learning Management System for efficient trial management. - April 30, 2024 - Anzu
Creative Biolabs: Summarizing Malaria Infection Mechanisms and Introducing Biotherapeutic Discovery
Creative Biolabs introduced the discovery of biomolecular approaches targeting Plasmodium, aiming to assist academia and the pharmaceutical industry in relieving the malaria health crisis. - April 25, 2024 - Creative Biolabs
Mirror Biologics, Inc. Appoints Elizabeth Czerepak as Chief Financial Officer and VP Corporate Development
Mirror Biologics, Inc., a clinical stage biopharmaceutical company announces the appointment of Elizabeth Adkins Czerepak as Chief Financial Officer (CFO) and Vice President of Corporate Development effective April 15, 2024. Ms. Czerepak has served as CFO of several biotechnology companies over... - April 18, 2024 - Mirror Biologics, Inc.
Ensuring Reliability for Healthcare Tech at Bio-IT World 2024 with NIX
NIX, a custom software developing company specializing in healthcare solutions, will be at Bio-IT World 2024. They prioritize reliability in their tech, offering secure, scalable, and compliant systems. With 30 years of experience and successful projects for industry leaders, NIX is a trusted partner for healthcare organizations seeking dependable technology solutions. - April 13, 2024 - NIX United
Saelig Introduces Sciospec ISX-3 Electrical Impedance Tomography System
The ISX-3 EIT system allows for simultaneous acquisition of impedance or potential signals on up to 256 electrodes over a broad frequency range of up to 1 MHz. - April 12, 2024 - Saelig Co. Inc.